Guest Editors
Leonardo Oliveira Reis, Department of Urology, Pontifical Catholic University of Campinas, São Paulo, 13086-900, Brazil. E-mail: reisleo.l@gmail.com
Mario I. Fernández, Department of Urology, Clínica Alemana de Santiago, Santiago, 7591046, Chile. E-mail: mariofernandez@udd.cl
Jose Ignacio Nolazco, Brigham and Women's Hospital, Harvard Medical School, Boston, 02115, USA. E-mail: JNolazco@bwh.harvard.edu
Summary
Urologic oncology is a rapidly evolving field, offering new perspectives and therapeutic avenues. Advances in modern approaches to diagnosing and treating genitourinary tumors enable strategic and tailored treatments that provide optimal oncological, functional, and quality of life outcomes. More precise diagnostic techniques help avoid late and over-diagnosis, while individualized therapies prevent over-treatment. New therapies have been developed based on improved prognostication capacity through the development of new biological predictors and strategies involving theranostic (combining therapeutic and diagnostic capabilities to both locate and treat cancer with targeted therapy) and immuno-oncological (supporting the natural immune response) knowledges. Liquid biopsies, from biological fluids, holds promise for non-invasive cancer monitoring and early detection of recurrence. Research into patient’s unique genetic profile provides insights into the aggressiveness of genitourinary cancer, helping to tailor treatment plans. Generative artificial intelligence and progressively autonomous robotic platforms grows in direction of improvement and systematization of minimally invasive surgical techniques. Ongoing research efforts aim to refine these methodologies further, enhancing outcomes for patients facing these complex cancers.
Keywords
Urologic Oncology, Genitourinary Oncology
Login
Register
Submit a Paper
Propose a Special lssue